Accelerate Diagnostics Stock Book Value Per Share

AXDX Stock

USD 1.64 0.03 1.80%

Accelerate Diagnostics fundamentals help investors to digest information that contributes to Accelerate Diagnostics' financial success or failures. It also enables traders to predict the movement of Accelerate Stock. The fundamental analysis module provides a way to measure Accelerate Diagnostics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Accelerate Diagnostics stock.

	Last Reported	Projected for Next Year
Book Value Per Share	(1.59)	(1.51)
Tangible Book Value Per Share	(1.59)	(1.51)

Book Value Per Share is likely to rise to -1.51 in 2024. Tangible Book Value Per Share is likely to rise to -1.51 in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Accelerate Diagnostics Company Book Value Per Share Analysis

Accelerate Diagnostics' Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.

Book Value per Share

Common Equity

Average Shares

More About Book Value Per Share | All Equity Analysis

Current Accelerate Diagnostics Book Value Per Share

(1.36) X

Most of Accelerate Diagnostics' fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Accelerate Diagnostics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Accelerate Book Value Per Share Driver Correlations

Understanding the fundamental principles of building solid financial models for Accelerate Diagnostics is extremely important. It helps to project a fair market value of Accelerate Stock properly, considering its historical fundamentals such as Book Value Per Share. Since Accelerate Diagnostics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Accelerate Diagnostics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Accelerate Diagnostics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Common Stock	Current Deferred Revenue	Treasury Stock	Property Plant Equipment	Intangible Assets	Good Will	Short Term Debt	Net Tangible Assets	Long Term Debt	Short Term Investments	Capital Surpluse	Long Term Debt Total	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.43	0.08	-0.21	0.14	0.25	0.51	1.0	-0.57	-0.1	-0.32	0.5	-0.47	-0.54	-0.06	0.4	0.51	0.81	0.35	0.66	-0.05	0.42	0.37	0.17
Total Stockholder Equity	0.43		-0.82	0.55	-0.18	-0.51	-0.55	0.47	-0.12	-0.25	0.66	-0.27	-0.09	-0.13	-0.25	1.0	-0.52	0.4	-0.39	-0.05	-0.22	0.55	0.56	-0.01
Net Debt	0.08	-0.82		-0.66	0.14	0.69	0.84	0.03	-0.14	0.23	-0.83	0.5	-0.11	-0.09	0.19	-0.83	0.82	0.2	0.56	0.4	0.16	-0.27	-0.3	0.1
Retained Earnings	-0.21	0.55	-0.66		-0.8	-0.86	-0.66	-0.16	0.52	-0.69	0.9	-0.93	0.44	0.47	-0.39	0.58	-0.59	-0.07	-0.98	-0.74	-0.35	0.72	0.74	0.11
Accounts Payable	0.14	-0.18	0.14	-0.8		0.65	0.21	0.11	-0.55	0.75	-0.56	0.81	-0.45	-0.47	0.45	-0.21	0.12	-0.13	0.83	0.57	0.42	-0.76	-0.79	-0.25
Net Receivables	0.25	-0.51	0.69	-0.86	0.65		0.66	0.21	-0.31	0.66	-0.85	0.82	-0.29	-0.33	0.29	-0.53	0.62	0.19	0.84	0.62	0.26	-0.5	-0.53	-0.11
Total Liab	0.51	-0.55	0.84	-0.66	0.21	0.66		0.47	-0.38	0.05	-0.89	0.65	-0.32	-0.34	0.2	-0.57	0.95	0.38	0.62	0.62	0.18	-0.07	-0.14	0.25
Total Current Assets	1.0	0.47	0.03	-0.16	0.11	0.21	0.47		-0.56	-0.12	-0.28	0.46	-0.47	-0.52	-0.08	0.45	0.47	0.82	0.31	0.63	-0.07	0.45	0.4	0.16
Common Stock	-0.57	-0.12	-0.14	0.52	-0.55	-0.31	-0.38	-0.56		-0.3	0.42	-0.68	0.64	0.46	-0.14	-0.1	-0.34	-0.39	-0.62	-0.64	-0.13	0.21	0.23	0.02
Current Deferred Revenue	-0.1	-0.25	0.23	-0.69	0.75	0.66	0.05	-0.12	-0.3		-0.41	0.61	-0.3	-0.17	0.09	-0.27	0.08	-0.09	0.71	0.43	0.06	-0.76	-0.67	-0.57
Treasury Stock	-0.32	0.66	-0.83	0.9	-0.56	-0.85	-0.89	-0.28	0.42	-0.41		-0.84	0.36	0.38	-0.34	0.68	-0.83	-0.18	-0.85	-0.66	-0.31	0.44	0.49	-0.03
Property Plant Equipment	0.5	-0.27	0.5	-0.93	0.81	0.82	0.65	0.46	-0.68	0.61	-0.84		-0.56	-0.58	0.27	-0.31	0.61	0.28	0.98	0.86	0.25	-0.53	-0.54	-0.15
Intangible Assets	-0.47	-0.09	-0.11	0.44	-0.45	-0.29	-0.32	-0.47	0.64	-0.3	0.36	-0.56		0.56	-0.12	-0.05	-0.29	-0.31	-0.52	-0.53	-0.11	0.18	0.2	0.02
Good Will	-0.54	-0.13	-0.09	0.47	-0.47	-0.33	-0.34	-0.52	0.46	-0.17	0.38	-0.58	0.56		-0.13	-0.07	-0.3	-0.33	-0.54	-0.56	-0.11	0.19	0.2	0.02
Short Term Debt	-0.06	-0.25	0.19	-0.39	0.45	0.29	0.2	-0.08	-0.14	0.09	-0.34	0.27	-0.12	-0.13		-0.26	-0.09	-0.14	0.32	0.16	1.0	-0.35	-0.6	0.62
Net Tangible Assets	0.4	1.0	-0.83	0.58	-0.21	-0.53	-0.57	0.45	-0.1	-0.27	0.68	-0.31	-0.05	-0.07	-0.26		-0.54	0.38	-0.42	-0.08	-0.23	0.57	0.58	-0.01
Long Term Debt	0.51	-0.52	0.82	-0.59	0.12	0.62	0.95	0.47	-0.34	0.08	-0.83	0.61	-0.29	-0.3	-0.09	-0.54		0.4	0.57	0.58	-0.11	-0.02	-0.01	0.02
Short Term Investments	0.81	0.4	0.2	-0.07	-0.13	0.19	0.38	0.82	-0.39	-0.09	-0.18	0.28	-0.31	-0.33	-0.14	0.38	0.4		0.19	0.51	-0.13	0.54	0.5	0.14
Capital Surpluse	0.35	-0.39	0.56	-0.98	0.83	0.84	0.62	0.31	-0.62	0.71	-0.85	0.98	-0.52	-0.54	0.32	-0.42	0.57	0.19		0.82	0.29	-0.66	-0.67	-0.16
Long Term Debt Total	0.66	-0.05	0.4	-0.74	0.57	0.62	0.62	0.63	-0.64	0.43	-0.66	0.86	-0.53	-0.56	0.16	-0.08	0.58	0.51	0.82		0.14	-0.29	-0.3	-0.05
Short Long Term Debt	-0.05	-0.22	0.16	-0.35	0.42	0.26	0.18	-0.07	-0.13	0.06	-0.31	0.25	-0.11	-0.11	1.0	-0.23	-0.11	-0.13	0.29	0.14		-0.31	-0.57	0.64
Net Invested Capital	0.42	0.55	-0.27	0.72	-0.76	-0.5	-0.07	0.45	0.21	-0.76	0.44	-0.53	0.18	0.19	-0.35	0.57	-0.02	0.54	-0.66	-0.29	-0.31		0.96	0.31
Net Working Capital	0.37	0.56	-0.3	0.74	-0.79	-0.53	-0.14	0.4	0.23	-0.67	0.49	-0.54	0.2	0.2	-0.6	0.58	-0.01	0.5	-0.67	-0.3	-0.57	0.96		0.08
Capital Stock	0.17	-0.01	0.1	0.11	-0.25	-0.11	0.25	0.16	0.02	-0.57	-0.03	-0.15	0.02	0.02	0.62	-0.01	0.02	0.14	-0.16	-0.05	0.64	0.31	0.08

Click cells to compare fundamentals

The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.

Competition

Predict Accelerate Diagnostics

Book Value Per Share Over Time

Accelerate Common Stock Shares Outstanding

Common Stock Shares Outstanding

13.1 Million

At this time, Accelerate Diagnostics' Common Stock Shares Outstanding is fairly stable compared to the past year.

In accordance with the recently published financial statements, the book value per share of Accelerate Diagnostics is about -1.365 times. This is 19.71% lower than that of the Life Sciences Tools & Services sector and 198.2% lower than that of the Health Care industry. The book value per share for all United States stocks is 100.07% higher than that of the company.

Accelerate Book Value Per Share Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Accelerate Diagnostics' direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Accelerate Diagnostics could also be used in its relative valuation, which is a method of valuing Accelerate Diagnostics by comparing valuation metrics of similar companies.

Accelerate Diagnostics is currently under evaluation in book value per share category among its peers.

Accelerate Fundamentals

	Return On Asset	-0.76
	Operating Margin	(2.88) %
	Current Valuation	79.13 M
	Shares Outstanding	25.04 M
	Shares Owned By Insiders	40.60 %
	Shares Owned By Institutions	17.45 %
	Number Of Shares Shorted	510.51 K
	Price To Earning	(15.18) X
	Price To Sales	3.36 X
	Revenue	12.06 M
	Gross Profit	3.3 M
	EBITDA	(49.77 M)
	Net Income	(61.62 M)
	Cash And Equivalents	36.77 M
	Cash Per Share	0.45 X
	Total Debt	39.22 M
	Debt To Equity	2.76 %
	Current Ratio	4.48 X
	Book Value Per Share	(1.36) X
	Cash Flow From Operations	(40.2 M)
	Short Ratio	7.77 X
	Earnings Per Share	(2.59) X
	Price To Earnings To Growth	(0.55) X
	Target Price	1.5
	Number Of Employees	134
	Beta	0.6
	Market Capitalization	41.07 M
	Total Asset	31.37 M
	Retained Earnings	(668.86 M)
	Working Capital	12.43 M
	Current Asset	91.68 M
	Current Liabilities	4.45 M
	Net Asset	31.37 M

About Accelerate Diagnostics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Accelerate Diagnostics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Accelerate Diagnostics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Accelerate Diagnostics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Accelerate Stock Analysis

When running Accelerate Diagnostics' price analysis, check to measure Accelerate Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Accelerate Diagnostics is operating at the current time. Most of Accelerate Diagnostics' value examination focuses on studying past and present price action to predict the probability of Accelerate Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Accelerate Diagnostics' price. Additionally, you may evaluate how the addition of Accelerate Diagnostics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC